  |
 | Up a level |
Paz-Ares, L. and Chen, Y. and Reinmuth, N. and Hotta, K. and Trukhin, D. and Statsenko, G. and Hochmair, M. J. and Özgüroglu, M. and Ji, J.H. and Garassino, M. C. and Voitko, O. and Poltoratskiy, A. and Musso, E. and Havel, L. and Bondarenko, I. and Losonczy, G. and Conev, N. and Mann, H. and Dalvi, T. B. and Jiang, H. and Goldman, J. W. (2022) Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open, Vol. 7 (no. 2). p. 100408. ISSN 2059-7029 (Online)
Shah, M.A. and Udrea, A.A. and Bondarenko, I. and Mansoor, W. and Sánchez, R.G. and Sarosiek, T. and Bozzarelli, S. and Schenker, M. and Gomez-Martin, C. and Morgan, C. and Özgüroglu, M. and Pikiel, J. and Kalofonos, H.P. and Wojcik, E. and Buchler, T. and Swinson, D. and Cicin, I. and Joseph, M. and Vynnychenko, I. and Luft, A.V. and Enzinger, P.C. and Salek, T. and Papandreou, C. and Tournigand, C. and Maiello, E. and Wei, R. and Ferry, D. and Gao, L. and Oliveira, J.M. and Ajani, J.A. (2022) Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers, Vol.14 (iss. 5). p. 1168. ISSN 2072-6694
